SEARCH

SEARCH BY CITATION

References

  • 1
    US Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Available from: http://www.Fda.Gov/Cder/Guidance/5460dft.Pdf[Accessed May 4, 2007]. Federal Register: February 3, 2006, Vol. 71. Number 23) Docket no. 2006D−0044.
  • 2
    Delasko JM, Cocchetto DM, Burke LB. Target Product Profile: Beginning with the end in mind. Update 2005: January/February, 36–9.
  • 3
    Rothman ML, Beltran P, Cappelleri JC, et al. Patient-Reported Outcomes: conceptual issues. Value Health 2007;10(Suppl. 2):S6675.
  • 4
    Snyder CF, Watson ME, Jackson JD, et al. Patient-reported outcome instrument selection: designing a measurement strategy. Value Health 2007;10(Suppl. 2):S7685.
  • 5
    Turner RR, Quittner AL, Parasuraman BM, et al. Patient-Reported Outcomes: instrument development and selection issues. Value Health 2007;10(Suppl. 2):S8693.
  • 6
    Fayers PM, Machin D, eds. Quality of Life: The Assessment, Analysis, and Interpretation of Patient-Reported Outcomes, 2nd edn. New York: Wiley, 2007.
  • 7
    Frost MH, Reeve BB, Liepa AM, et al. What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health 2007;10(Suppl. 2):S94105.
  • 8
    Cronbach LJ. Coefficient alpha and the internal structure of test. Psychometrika 1951;16:297334.
  • 9
    Bollen KA, Lennox RD. Conventional wisdom on measurement: Structural equation perspective. Psychol Bull 1991;110:30514.
  • 10
    Patrick D, Erickson P. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. New York: Oxford University Press, 1993.
  • 11
    Sloan JA, Dueck AC, Erickson PA, et al. Analysis and interpretation of results based on patient-reported outcomes. Value Health 2007;10(Suppl. 2): S10615.
  • 12
    Revicki DA, Erickson PA, Sloan JA, et al. Interpreting and reporting results based on patient-reported outcomes. Value Health 2007;10(Suppl. 2):S11624.
  • 13
    Schwarz N, Sudman S, eds. Context Effects in Social and Psychological Research. New York: Springer-Verlag, 1992.
  • 14
    Schuman H, Presser S. Questions and Answers in Attitude Surveys. New York: Academic Press,1981.
  • 15
    Groves RM, Fowler FJ, Jr, Couper MP, et al. Survey Methodology. New York: Wiley, 2004.
  • 16
    US Food and Drug Administration. ICH E9 ‘Statistical Principles for Clinical Trials.’ Available from: http://www.fda.gov/cder/guidance/ICH_E9-fnl.pdf[Accessed May 4, 2007].
  • 17
    The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medical Products: ‘Points to consider on multiplicity issues in clinical trials.’ Available from: http://www.emea.eu.int/pdfs/human/ewp/090899en.pdf[Accessed May 4, 2007].
  • 18
    Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC Press, 2002.
  • 19
    Guyatt GH, Juniper EF, Walter SD, et al. Interpreting treatment effects in randomized trials. BMJ 1998;316:6903.
  • 20
    Premarin® Product Labeling. November 2005.
  • 21
    Aricept® Product Labeling. March 2005.